Ratings Chong Kun Dang Pharmaceutical Corp.

Equities

A185750

KR7185750007

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-05-06 pm EDT			5-day change	1st Jan Change
103,100 ^KRW	+1.18%		-1.15%	-21.24%

Apr. 25	Tranche Update on Chong Kun Dang Pharmaceutical Corp.'s Equity Buyback Plan announced on January 23, 2024.	CI
Jan. 23	Chong Kun Dang Pharmaceutical Corp. announces an Equity Buyback for KRW 15,000 million worth of its shares.	CI

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

The company is in a robust financial situation considering its net cash and margin position.
The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
Given the positive cash flows generated by its business, the company's valuation level is an asset.

Weaknesses

As estimated by analysts, this group is among those businesses with the lowest growth prospects.
The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
The company is not the most generous with respect to shareholders' compensation.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
CHONG KUN DANG PHARMACEUTICAL CORP.	-21.24%	969M		-
SUN PHARMACEUTICAL INDUSTRIES LTD.	+20.69%	43.57B		B-
OTSUKA HOLDINGS CO., LTD.	+20.70%	22.7B		B+
SANDOZ GROUP AG	+11.68%	14.32B		-
CIPLA LIMITED	+11.58%	13.42B		B+
ZYDUS LIFESCIENCES LIMITED	+44.90%	11.83B		B
ONO PHARMACEUTICAL CO., LTD.	-8.84%	6.98B		B+
THE MEDICINES COMPANY	-0.05%	6.79B	-	-
STADA ARZNEIMITTEL	-8.87%	5.73B	-	-
ASPEN PHARMACARE HOLDINGS LIMITED	+12.33%	5.51B		B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes